Research programme: ophthalmologic siRNA therapeutics - Sylentis

Drug Profile

Research programme: ophthalmologic siRNA therapeutics - Sylentis

Alternative Names: SYL 1801; SYL-040003; SYL-054003

Latest Information Update: 11 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sylentis
  • Class Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • Discontinued Glaucoma; Ocular pain

Most Recent Events

  • 01 Apr 2018 Preclinical trials in Age-related macular degeneration in Spain (Topical), before April 2018
  • 12 Jul 2016 Discontinued - Preclinical for Glaucoma in Spain (Topical)
  • 12 Jul 2016 Discontinued - Preclinical for Ocular pain in Spain (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top